In The News,
In The News,
Written by Virgil Dickson
***excerpt***
This approach separates the Trump administration from prior ones, according to Lindsay Bealor Greenleaf, a director of healthcare consulting firm ADVI. Instead of merely condemning the drug industries for prices, it is angling to use the drug supply chain to reduce costs.
***end excerpt***
***
[/el-text]